The Fox Chase-Temple bone marrow transplant program recently earned reaccreditation for three years from the Foundation for the Accreditation of Cellular Therapy (FACT). This achievement reaffirms the expertise and dedication of the faculty and the high quality of care provided to patients through the hematology program.
The National Comprehensive Cancer Network (NCCN) has honored Paul F. Engstrom, MD, acting chair of medical oncology and senior vice president of extramural research programs, with its prestigious Rodger Winn Award in recognition of his role in developing the organization’s widely used clinical guidelines. NCCN CEO Robert W. Carlson, MD, calls him “the ‘father’ of the NCCN Clinical Practice Guidelines in Oncology,” noting Engstrom’s “demonstrated leadership and dedication to the welfare of patients” and active membership in NCCN since its inception.
For the latest in its Cancer Conversations series — public talks in which physicians, authors, filmmakers, and others discuss cancer-related topics — Fox Chase welcomed George Johnson, former writer and editor for The New York Times. Johnson discussed his book The Cancer Chronicles: Unlocking Medicine’s Deepest Mystery, in which he recounts his journey into the world of oncology following his wife’s diagnosis with metastatic cancer and details the wealth of insights now emerging about cancer’s fundamental nature and origins.
Fox Chase investigators presented the following research at the American Society of Clinical Oncology’s Annual Meeting in Chicago, Ill., in May. Research Shows Overall Survival Benefit for Patients with Stage III Soft Tissue Sarcomas Fox Chase Researchers Find More Patients with Ovarian Cancer Are Receiving Chemotherapy Before Surgery Fox Chase Study Finds that Genetic Profile Predicts Which Bladder Cancer Patients Will Benefit from Early Chemotherapy Fox Chase Trial Uncovers Potential Dangers of Chemotherapy Regimen for Bladder Cancer Patients Hepatitis C Reactivation Does Not Worsen Survival Outcomes for HIV+ Patients Diagnosed with Lymphoma Identification of Central Nervous System Involvement at Diagnosis … Continue Reading »
A number of Fox Chase investigators presented research findings at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., in April. Medical oncologist Ranee Mehra, MD, and colleagues found that a quartet of proteins that play critical roles in cell replication, cell death, and DNA repair could lead to better targets for therapy against treatment-resistant head-and-neck squamous cell cancers by showing a correlation between the expression levels of these proteins in head and neck cancers negative for human papilloma virus (HPV). These tumors have a poorer prognosis than HPV-positive head and neck cancers. Dr. Mehra’s research … Continue Reading »
A study of a new investigational compound for advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), co-authored by Fox Chase medical oncologist Ranee Mehra, MD, has led to FDA approval of this treatment for patients who have progressed on prior therapy. Continue Reading »
Stephen C. Rubin, MD, joined Fox Chase in March as chief of gynecologic oncology. A nationally known expert in the management of ovarian cancer, Rubin’s interests include minimally invasive gynecologic surgery, hereditary ovarian cancer, and ovarian cancer clinical trials.
Q: How did you decide on a career in gynecologic oncology?
You hear a lot about the merits of multidisciplinary cancer care, combining the various therapeutic disciplines – surgery, chemotherapy, and radiation therapy. Gynecologic oncology is the only true multidisciplinary Continue Reading »
A team of Temple researchers led by Fox Chase epidemiologist Camille Ragin, MPH, PhD, has received a grant of more than $1.7 million from the American Cancer Society (ACS) to examine how genetics and the environment interact to influence racial disparities in patients with head and neck cancer. A founding member of the African-Caribbean Cancer Consortium (AC3), since 2006 Ragin has investigated the prevalence and outcomes of cancer for different racial groups in the United States and abroad. Continue Reading »
Based on research at Fox Chase that has illuminated heat shock protein 90 (HSP90) as a potentially important therapeutic target in several diseases, translational researchers are launching clinical studies to test the efficacy of therapies that inhibit this protein. HSP90 mediates activity for numerous cell-signaling pathways and transcription factors, and is over-expressed in cancerous cells. Continue Reading »